Clinical Trials Logo

Clinical Trial Summary

This study is a randomized-control pilot study that aims to evaluate Time Limited Eating (TLE) in the pediatric T1D population, implemented within the first six months after diagnosis. This period is characterized by residual β-cell function, during which TLE may have the ability to preserve and improve β-cell activity, indicated by increased C-peptide production. The investigators aim to assess the feasibility, acceptability, and safety of TLE in the pediatric T1D population, as well as to investigate the impact of TLE on β-cell function, insulin sensitivity, and glycemic control.


Clinical Trial Description

This will be a two-armed study with an intervention and control group. Feasibility and acceptability will be assessed by using questionnaires. Safety will be indicated by hypoglycemia occurrence. β-cell function and insulin sensitivity will be evaluated using mixed meal tolerance test with C-peptide and glucose levels. Glycemic control will be indicated by continuous glucose monitor (CGM). Block randomization will be utilized to ensure the groups are balanced in terms of ethnicity and BMI. The study period will be 13 weeks in duration, including a week-long run-in period and a 12 week intervention period. There will be two in-person study visits at week 0 and week 13. Anthropometrics including weight, height, and pubertal status will be evaluated at these times. Group 1- Standard Care (control) - includes a minimum 12-hour feeding window - no caloric restriction will be used - will wear a continuous glucose monitor Group 2 - TLE (intervention) - includes an 8-hour feed/16-hour fast for 7 days per week - will be instructed to consume all of their calories from 11 AM to 7 PM - can consume non-caloric beverages (water, tea, coffee) during the fasting period - will wear a continuous glucose monitor - no caloric restriction will be used ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05031429
Study type Interventional
Source Children's Hospital Los Angeles
Contact Casey Berman, MD
Phone 323-361-8848
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date September 1, 2021
Completion date July 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Not yet recruiting NCT04674384 - Manchester Intermittent and Daily Diet Type 1 Diabetes App Study (MIDDAS-Type 1) N/A
Active, not recruiting NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Not yet recruiting NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Enrolling by invitation NCT05036343 - A Study to Assess the Effect of Smart Insulin Pens on Glycemic Control and Diabetes-related Burdens N/A
Not yet recruiting NCT05000021 - Telemedicine-Delivered Cognitive Behavioral Therapy to Reduce Diabetes Distress N/A
Not yet recruiting NCT04416737 - Evaluating the Benefits of Physiologic Insulin Delivery N/A
Not yet recruiting NCT04933851 - ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes Phase 2
Recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02897557 - Insulet Artificial Pancreas Early Feasibility Study N/A
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
Active, not recruiting NCT02442544 - Prebiotic Fiber Supplement in T1DM Children Early Phase 1
Completed NCT02544321 - Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes Phase 2
Not yet recruiting NCT02547337 - Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes N/A
Completed NCT02760303 - Reducing Stress in Adolescents and Young Adults With Type 1 Diabetes to Improve Diabetes Care N/A